- Home
- FRD vs ENTX Comparison
FRD vs ENTX Comparison
Compare FRD & ENTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FRD
- ENTX
- Stock Information
- Founded
- FRD 1965
- ENTX 2010
- Country
- FRD United States
- ENTX Israel
- Employees
- FRD N/A
- ENTX N/A
- Industry
- FRD Steel/Iron Ore
- ENTX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- FRD Industrials
- ENTX Health Care
- Exchange
- FRD Nasdaq
- ENTX Nasdaq
- Market Cap
- FRD 122.3M
- ENTX 104.0M
- IPO Year
- FRD N/A
- ENTX 2018
- Fundamental
- Price
- FRD $16.90
- ENTX $2.01
- Analyst Decision
- FRD
- ENTX Strong Buy
- Analyst Count
- FRD 0
- ENTX 1
- Target Price
- FRD N/A
- ENTX $10.00
- AVG Volume (30 Days)
- FRD 16.5K
- ENTX 37.4K
- Earning Date
- FRD 06-13-2025
- ENTX 05-09-2025
- Dividend Yield
- FRD 0.97%
- ENTX N/A
- EPS Growth
- FRD N/A
- ENTX N/A
- EPS
- FRD 0.81
- ENTX N/A
- Revenue
- FRD $447,616,000.00
- ENTX $223,000.00
- Revenue This Year
- FRD N/A
- ENTX N/A
- Revenue Next Year
- FRD N/A
- ENTX N/A
- P/E Ratio
- FRD $20.68
- ENTX N/A
- Revenue Growth
- FRD N/A
- ENTX N/A
- 52 Week Low
- FRD $12.24
- ENTX $1.41
- 52 Week High
- FRD $19.12
- ENTX $2.79
- Technical
- Relative Strength Index (RSI)
- FRD 57.10
- ENTX 51.11
- Support Level
- FRD $15.51
- ENTX $1.69
- Resistance Level
- FRD $17.27
- ENTX $2.15
- Average True Range (ATR)
- FRD 0.69
- ENTX 0.13
- MACD
- FRD 0.07
- ENTX 0.00
- Stochastic Oscillator
- FRD 78.09
- ENTX 69.57
About FRD Friedman Industries Inc.
Friedman Industries Inc is engaged in the manufacturing and processing of steel products. The company's operating segments include flat-roll products and Tubular Products. It generates maximum revenue from the flat-roll products segment. The company's products and services include Temper Pass, Cut-To-Length, Whole Coils, Toll Processing, Electric Resistance Welded Pipe (ERW), New Mill Secondary, and Pipe Finishing Services.
About ENTX Entera Bio Ltd.
Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to significantly shift a treatment paradigm. Its product candidates are; EB613 for the treatment of osteoporosis and EB612 for the treatment of hypoparathyroidism are first-in-class mini tablet formulations of synthetic human PTH (1-34) (teriparatide), designed to have differing pharmacokinetic, or PK, profiles.